Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer

Introduction: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019. The active antiviral component nirmatrelvir in Paxlovid is co-formulated with ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor. Many oral targ...

Full description

Bibliographic Details
Main Authors: Kaleem Anwar, PharmD, Lee Nguyen, PharmD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD, Alexandre Chan, PharmD, MPH
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:JTO Clinical and Research Reports
Subjects:
Drug-drug interaction
Paxlovid
Ritonavir
Nirmatrelvir
Lung cancer
Supportive care
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432200176X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432200176X

Similar Items